Literature DB >> 6339712

Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production.

R R Butler, W C Wise, P V Halushka, J A Cook.   

Abstract

We investigated the effects of the thromboxane synthetase inhibitor 7-(1-imidazolyl)heptanoic acid (7-IHA) and the fatty acid cyclooxygenase inhibitors indomethacin or ibuprofen in the treatment of fecal peritonitis in the rat. The effects of gentamicin alone and in combination with reduction of arachidonic acid metabolism by either treatment with indomethacin or essential fatty acid deficiency was also investigated. 7-IHA (60 mg/kg), administered i.p. 30 min before i.p. instillation of a fecal suspension, significantly reduced the plasma levels of immunoreactive (i) TxB2 from 1066 +/- 194 pg/ml (N = 14) to nondetectable (less than 200 pg/ml; N = 9) (P less than .01) at 1 hr and from 1695 +/- 218 (N = 16) to 508 +/- 56 pg/ml (N = 6) (P less than .01) at 4 hr after instillation of feces. In contrast, the levels of i6-keto-prostaglandin (PG)F1 alpha, the stable metabolite of prostacyclin, were significantly elevated by 7-IHA pretreatment from vehicle-treated septic control levels of 3777 +/- 414 (N = 16) to 5185 +/- 467 pg/ml (N = 9) (P less than .05) at 1 hr. Plasma i6-keto-PGF1 alpha at 4 hr in 7-IHA-treated rats (5503 +/- 665 pg/ml) (N = 6) was not different from vehicle-treated controls. Survival associated with fecal peritonitis was not altered by 7-IHA pretreatment. Indomethacin (10 mg/kg) or ibuprofen (5 mg/kg) administered i.p. 30 min before the fecal suspension significantly decreased both iTxB2 and i6-keto-PGF1 alpha, plasma levels when measured at 4 hr and prolonged survival time (P less than .05). Fibrinogen/fibrin degradation products were elevated (P less than .01) during fecal peritonitis and were reduced by indomethacin (P less than .01) or 7-IHA (P less than .05). Gentamicin significantly increased mean survival time from 8.6 +/- 0.2 (N = 50) to 23.8 +/- 2.6 hr (N = 16) (P less than .01). Gentamicin in combination with indomethacin or essential fatty acid deficiency further improved mean survival time and resulted in long-term survivals (greater than 48 hr) of 35 (N = 17) and 30% (N = 7), respectively (P less than .01 compared with gentamicin). Gentamicin pretreatment did not significantly alter plasma iTxB2 levels, but decreased i6-keto-PGF1 alpha from 9465 +/- 792 (N = 7) to 3096 +/- 1,174 pg/ml (N = 5; P less than .01) at 6 hr after induction of fecal peritonitis. These studies raise the possibility that inhibition of fatty acid cyclooxygenase may be a useful adjunct to antibiotic therapy in the treatment of septic shock.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339712

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.

Authors:  Jennifer M Dolan; Jason B Weinberg; Edmund O'Brien; Anya Abashian; Megan C Procario; David M Aronoff; Leslie J Crofford; Marc Peters-Golden; Lindsay Ward; Peter Mancuso
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-04-08       Impact factor: 5.464

Review 2.  Corticosteroids, nonsteroidal anti-inflammatory drugs, and naloxone in the sepsis syndrome.

Authors:  W M Long; C L Sprung
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 3.  Intensive care.

Authors:  S Sinclair; M Singer
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

Review 4.  Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.

Authors:  H A Ball; J A Cook; W C Wise; P V Halushka
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

5.  E-prostanoid 2 receptor signaling suppresses lung innate immunity against Streptococcus pneumoniae.

Authors:  David M Aronoff; Ingrid L Bergin; Casey Lewis; Deepti Goel; Edmund O'Brien; Marc Peters-Golden; Peter Mancuso
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-04-02       Impact factor: 3.072

Review 6.  Cyclooxygenase inhibition in sepsis: is there life after death?

Authors:  David M Aronoff
Journal:  Mediators Inflamm       Date:  2012-05-14       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.